BioArctic
Develops treatments and diagnostics for neurodegenerative disorders like Alzheimer's and Parkinson's.
BIOA | ST
Overview
Corporate Details
- ISIN(s):
- SE0010323303 (+1 more)
- LEI:
- 549300Y0OI2WVUNHLC33
- Country:
- Sweden
- Address:
- Warfvinges väg 35, 112 51 Stockholm
- Website:
- https://www.bioarctic.se/en/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
BioArctic is a Swedish research-intensive biopharmaceutical company focused on developing novel, disease-modifying treatments and diagnostics for neurodegenerative disorders. The company's core mission is to address the underlying causes of diseases such as Alzheimer's and Parkinson's. Its research is centered on developing innovative drugs and antibodies that target the root mechanisms of nerve cell damage and misfolded proteins, aiming to provide effective solutions for significant unmet medical needs within the central nervous system.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-01-30 00:30 |
Lecanemab receives priority review status in Japan
|
English | 205.8 KB | ||
| 2023-01-30 00:30 |
Lecanemab erhåller prioriterad granskning i Japan
|
Swedish | 201.0 KB | ||
| 2023-01-27 00:30 |
European Medicines Agency accepts Marketing Authorization Application for lecan…
|
English | 200.5 KB | ||
| 2023-01-27 00:30 |
Ansökan om marknadsgodkännande av lecanemab för behandling av tidig Alzheimers …
|
Swedish | 198.9 KB | ||
| 2023-01-19 09:50 |
BioArctic’s Chairman of the Board Wenche Rolfsen declines re-election
|
English | 140.5 KB | ||
| 2023-01-19 09:50 |
BioArctics styrelseordförande Wenche Rolfsen avböjer omval
|
Swedish | 139.5 KB | ||
| 2023-01-16 01:30 |
BioArctic’s partner Eisai submits marketing authorization application for lecan…
|
English | 270.4 KB | ||
| 2023-01-16 01:30 |
BioArctics partner Eisai lämnar in ansökan om marknadsgodkännande av lecanemab …
|
Swedish | 220.2 KB | ||
| 2023-01-11 00:30 |
BioArctics partner Eisai lämnar in ansökan om marknadsgodkännande av lecanemab …
|
Swedish | 216.6 KB | ||
| 2023-01-11 00:30 |
BioArctic’s partner Eisai submits marketing authorization application for lecan…
|
English | 262.2 KB | ||
| 2023-01-07 05:30 |
BioArctic’s partner Eisai submits supplemental Biologics License Application to…
|
English | 261.9 KB | ||
| 2023-01-07 05:30 |
BioArctics partner Eisai lämnar in kompletterande registreringsansökan till FDA…
|
Swedish | 207.5 KB | ||
| 2023-01-06 20:30 |
FDA godkänner Leqembi™ (lecanemab-irmb) via det accelererade förfarandet för be…
|
Swedish | 219.1 KB | ||
| 2023-01-06 20:30 |
FDA approves LEQEMBI™ (lecanemab-irmb) under the Accelerated Approval pathway f…
|
English | 268.8 KB | ||
| 2022-11-30 18:00 |
Antal aktier och röster i BioArctic AB (publ) per den 30 november 2022
|
Swedish | 138.5 KB |
Automate Your Workflow. Get a real-time feed of all BioArctic filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BioArctic
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BioArctic via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-02-13 | Gunilla Osswald | Other | Sell | 40,000 | 8,821,200.00 SEK |
| 2025-02-13 | Gunilla Osswald | Other | Other | 40,000 | 3,344,000.00 SEK |
| 2025-02-13 | Sten Mikael Moge | Other | Sell | 6,000 | 1,323,180.00 SEK |
| 2025-02-13 | Sten Mikael Moge | Other | Other | 6,000 | 501,600.00 SEK |
| 2025-02-13 | Johanna Margareta Fälting | Other | Sell | 1,500 | 330,795.00 SEK |
| 2025-02-13 | Johanna Margareta Fälting | Other | Other | 2,500 | 209,000.00 SEK |
| 2025-02-13 | Johanna Margareta Fälting | Other | Other | 1,500 | 125,400.00 SEK |
| 2025-01-10 | Mikael Smedeby | Other | Buy | 730 | 148,920.00 SEK |
| 2024-12-19 | Oskar Bosson | Other | Sell | 2,000 | 446,000.00 SEK |
| 2024-12-19 | Oskar Bosson | Other | Sell | 871 | 195,626.60 SEK |
Peer Companies
